Table 3. Early discontinuation of anti-glaucoma therapy, by patients and first prescription characteristics.
| Early discontinuation | No | Yes | Total | a P |
| Total | 2138 (88.5) | 277 (11.5) | 2415 (100) | |
| Gender | 0.618 | |||
| Male | 867 (88.9) | 108 (11.1) | 975 (40.4) | |
| Female | 1271 (88.3) | 169 (11.7) | 1440 (59.6) | |
| Age group | <0.001 | |||
| 18-44y | 73 (78.5) | 20 (21.5) | 93 (3.9) | |
| 45-64y | 468 (83.0) | 96 (17.0) | 564 (23.4) | |
| 65y or more | 1597 (90.8) | 161 (9.2) | 1758 (72.8) | |
| First prescription drug number | <0.001 | |||
| 1 | 1283 (84.9) | 229 (15.1) | 1512 (62.6) | |
| 2 | 479 (91.6) | 44 (8.4) | 523 (21.7) | |
| 3 or more | 376 (98.9) | 4 (1.1) | 380 (15.7) | |
| Pharmacological class | <0.001 | |||
| S01EA | 33 (84.6) | 6 (15.4) | 39 (1.6) | |
| S01EC | 76 (80.0) | 19 (20.0) | 95 (3.9) | |
| S01ED | 695 (85.5) | 118 (14.5) | 813 (33.7) | |
| S01EE | 479 (84.8) | 86 (15.2) | 565 (23.4) | |
| Fixed combinations | 855 (94.7) | 48 (5.3) | 903 (37.4) | |
| Brand/generic classification | 0.283 | |||
| Generic drug | 25 (78.1) | 7 (21.9) | 32 (2.1) | |
| Brand name drug | 1258 (85.0) | 222 (15.0) | 1480 (97.9) | |
| Pharmaceutical form of the initial drug | 0.964 | |||
| Dropper bottle | 1193 (84.8) | 214 (15.2) | 1407 (93.1) | |
| Single dose container | 65 (85.5) | 11 (14.5) | 76 (5.0) | |
| Orally | 25 (86.2) | 4 (13.8) | 29 (1.9) |
aChi-square test. S01EA: Sympathomimetics in glaucoma therapy; S01EC: Carbonic anhydrase inhibitors; S01ED: Beta blocking agents; S01EE: Prostaglandin analogues.
n (%)